Document:

Exhibit 10.2 Xfone Inc.

EXHIBIT 10.2

                          AGREEMENT WITH BEADROS ASARE

THIS CONSULTING AGREEMENT ("Agreement") is made and entered into the 1st day of
January, 2002 by and between Xfone, Inc. a Nevada ("Company") and Beadros Asare
("Consultant").

The Company wishes to engage the services of Consultant to perform Edgarizing
services for the Company in exchange for shares of common stock of the Company;

The Consultant represents that it has no prior or existing legally binding
obligations that are in conflict with its entering into this Agreement; and

The Consultant is willing to be so retained on the terms and conditions of this
Agreement.

NOW, THEREFORE, in consideration of the promises and the mutual agreements
hereinafter set forth, the parties hereto agree as follows:

1.   Engagement. The Company hereby retains Consultant to perform edgarizing
services and Consultant hereby accepts such engagement on the terms and
conditions hereinafter set forth.

2.   Term. This Agreement shall be in effect from the date of execution until
June 30, 2002.

3.   Duties of Consultant. The Company retains Consultant to provide advice on
all matters pertaining to the Edgar filings of the Company, and Consultant shall
make all Edgar filings on behalf of the Company during the term of this
agreement from time to time as requested by the Company.

     The Consultant shall not provide any of the following services: promotion
of the Company's securities, either indirectly or directly; maintaining a market
for the Company's securities, either indirectly or directly; capital raising
transactions; marketing services; or investor and/or shareholder relations
services.

     In his capacity as advisor and consultant to management of the Company,
Consultant shall be required to devote up to 40 hours per month to the business
of the Company. Consultant shall also be available, at the mutual convenience of
the parties, to evaluate specific matters or problems submitted to Consultant by
management of the Company.

     Consultant shall render the services required in this Agreement as an
independent contractor. Deadlines in respect of the service and functions of
Consultant shall be mutually agreed upon.

     Consultant shall use his best efforts to advance the business and welfare
of the Company and shall not intentionally take any action adverse to the best
interests of the Company.

4.   Compensation. As full and complete compensation for any and all services
(except out-of-pocket expenses approved by the Company) that Consultant shall
render to the Company, the Company shall make a one-time grant of 3,500 shares
of the Company's Common Stock to be registered on Form S-8.

5.   Disclosure of Information. Consultant recognizes and acknowledges as a
result of his engagement by the Company, he will have access to discover
information which is of a proprietary manner to the Company, including methods,
inventions, improvements, trade secrets, or discoveries, whether patentable or
not, and similar information relating to the Company's products and services. In
addition, information will or has been disclosed to Consultant, or has been
discovered by Consultant, concerning marketing plans, processes, products,
apparatus, techniques, know-how, trade secret, strategies, customer lists, and
technical requirements of customers of the Company. Consultant agrees that he
will not, without the prior written approval of the Company, disclose any such
proprietary information of the Company to anyone not in the employ of the
Company, or use any such information other than for the purposes of this
Agreement. Consultant agrees that he will not allow any other person engaged by
him to have access to any of the proprietary information unless he first obtains
such person's agreement not to disclose or use such information, and such
agreement is binding upon the Company, Consultant, and such third person.

     These obligations shall not apply, however, to information which is or
becomes generally available to the public through no fault of Consultant.

6.   Notices. Any notice required or permitted to be given under this Agreement
shall be sufficient if in writing and personally delivered, or if sent by
certified mail, postage prepaid to its residence in the case of Consultant, its
principal office in the case of the Company and shall be effective upon deposit
into the United States Postal Service, or in the case of personal delivery when
actually delivered.

7.   Waiver. The waiver by the Company of a breach of any provision of this
Agreement by Consultant shall not operate or be construed as a waiver of any
subsequent breach by Consultant.

8.   Binding Effect. This Agreement shall be binding upon and shall inure to the
benefit of the parties hereto, their respective heirs, representatives,
successors, and assigns, but shall not be assignable by Consultant without the
prior written consent of the Company.

9.   Severability. If any provision of this Agreement is held to be contrary to
law, that provision shall be deemed severable from the balance of this
Agreement, and the balance of this Agreement shall remain in force between the
parties to the fullest extent permitted by law.

10.  Entire Agreement. This Agreement shall be deemed to express, embody, and
supersede all previous understandings, agreements and commitments, whether
written or oral, between the parties hereto with respect to the subject matter
hereof and to fully and finally set forth the entire agreement between the
parties hereto. No modifications shall be binding unless stated in writing and
signed by both parties hereto with the approval of the President of the Company.

11.  Governing Law; Venue; Arbitration. This Agreement shall be governed by the
laws of the State of Florida. Any dispute involving or affecting this Agreement
or the services to be performed shall be determined and resolved by binding
arbitration in the County of Palm Beach, State of Florida, in accordance with
the Commercial Arbitration Rules of the American Arbitration Association.

12.  Prior Agreements. This Agreement supersedes and renders null and void all
prior written or oral agreements by and between the Company or its affiliates
and Consultant, except as provided herein or in any amendments or addendums
hereto.

13.  Counterparts. This Agreement may be signed in two counterparts, but both of
which placed together, shall constitute one instrument.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective
the date set forth above.

     COMPANY:
     Xfone, Inc.

     By: /s/ Guy Nissenson
     Name: Guy Nissenson, President

     CONSULTANT:

     By: /s/ Beadros Asare
     Name: Beadros AsareExhibit 10.2 for Omega Med Corp

Exhibit 10.2

                            PATENT LICENSE AGREEMENT
                  Between Ulrich D. Cochran and OMEGA-MED Inc.

Ulrich D. Cochran, residing at 1879 Baker ST NE, Palm Bay, FL 32907 being the
legal owner of the following United States patents does hereby grant to
OMEGA-MED, Inc., 3930 Oregon ST., San Diego, CA 92104 an exclusive license under
# 4,773,900 and a non-exclusive license under # 4,581,856, to manufacture within
the continental limits of the U.S.A. and sell product worldwide under the
following terms and conditions.

1. PAYMENT FOR ISSUANCE OF LICENSE

        In lieu of cash, I will accept 1,000,000 shares of OMEGA-MED stock to be
issued upon request.

2. ROYALTY SCHEDULE

        During each fiscal year so long as product is manufactured under any
patent claim covering either the product or its manufacture, royalties will be
paid by OMEGA-MED to the patent owner based on gross receipts from the sale of
product, wherever sold.

Royalties due for each fiscal year will be calculated as follows.

        first  $000.00 up to $1,000,000.00      6%
        second $1M up to 3M                     5%
        third  $3M up to 6M                     4%
               all over $6M                   3.5%

        Gross sales means sale price to the final end user minus reasonable
trade discounts or commissions paid to independent salesmen or credit for goods
returned.

3. MINIMUM ROYALTY PAYMENT

        Starting with the date of first sale of licensed product, a payment of
$50,000 will be made at the beginning of each fiscal quarter.  At the close of
the fiscal year, royalties due will be credited against these payments.  A
certified account of all product manufactured whether sold or not, will be
provided to the licensor.

4. ADDITIONAL PATENTS AND TECHNOLOGY

        Certain design improvements and attachments are not included in the
present patent or working models.  The manufacturing process is unique and
original and includes specially designed equipment for assembly and quality
assurance.  These are vital to low unit cost structure, product reliability and
flexibility in manufacturing the product mis.  The inventors intend to apply for
additional patents on design improvements as well as special machinery and
instrumentation for use in the manufacturing process.  Such patents if issued,
will be included under this license provided they apply exclusively to the
products manufactured by OMEGA-MED.  In the event that the patents include other
applications not competitive with products manufactured by OMEGA-MED, then a
non-exclusive license will be granted.

5. RIGHT TO ASSIGN PATENTS

        Any patents covered by this agreement may be assigned to any other
entity provided that the terms of this agreement are preserved by the assignee.

6. CONFIDENTIALITY

        Since much of the manufacturing technology as well as certain ancillary
equipment for the pump itself have not yet been patented, the premature
disclosure of such information could hazard the patent process.  We therefore
require that any publicity or additional Internet material be submitted and
approved by Cochran before it is release to the public.

7. DURATION OF LICENSE AGREEMENT

        License terms shall remain in force so long as any claim of any patent,
whether domestic or foreign, is applicable to the product, its manufacture or
any other product derived from the original.

May 15, 1998

/s/ Ulrich D. Cochran

Ulrich D. Cochran

Accepted, OMEGA-MED, Inc.

/s/ Harold Letson

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}]]